Completed PHASE2 INTERVENTIONAL NCT00034619
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Sponsor: Eli Lilly and Company
Conditions
Colorectal Cancer
Interventions
ALIMTA Oxaliplatin
Updated 5 times since 2017 Last updated: Jul 18, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00034619, this PHASE2 trial focuses on Colorectal Cancer and remains completed. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Eli Lilly and Company
Data source: Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .